Cart is empty
View Cart
Subtotal: $0.00
JOIN NOW!
  • ABOUT US
    • Board of Directors
    • Benefits
    • Volunteering
      • Volunteer Opportunities
      • EDEI Committee
      • Education
      • Emerging Leaders
      • Local GAMP CoP
      • Membership
      • Product Show
      • Social
      • Student Development
      • Women in Pharma®
    • Students
      • Student Chapters
      • Career Workshop
      • Scholarships
    • Chapter Awards
      • NEW Chapter Awards 2024
    • Sponsors
    • Contact Us
  • EVENTS
    • Chapter Calendar
    • Educational Programs
    • Social Events
    • Student Activities
    • Product Show
    • Past Events
  • RESOURCES
    • Scholarship Foundation
      • Scholarship Application
    • Podcast
    • Documents
    • Chapter YouTube Channel
    • ISPE Publications
    • ISPE Guidance Documents
    • Member Directory
    • ISPE Training
    • ISPE Communities of Practice
  • BLOG
    • Boston Chapter Blog
      • Contribute
    • ISPE Blog
  • CAREERS
    • Job Board
    • Post a Job
  • Gallery
  • SCHOLARSHIP FOUNDATION
    • About the Foundation
    • Apply for a Scholarship
    • Donate
  • ABOUT US
    • Board of Directors
    • Benefits
    • Volunteering
      • Volunteer Opportunities
      • EDEI Committee
      • Education
      • Emerging Leaders
      • Local GAMP CoP
      • Membership
      • Product Show
      • Social
      • Student Development
      • Women in Pharma®
    • Students
      • Student Chapters
      • Career Workshop
      • Scholarships
    • Chapter Awards
      • NEW Chapter Awards 2024
    • Sponsors
    • Contact Us
  • EVENTS
    • Chapter Calendar
    • Educational Programs
    • Social Events
    • Student Activities
    • Product Show
    • Past Events
  • RESOURCES
    • Scholarship Foundation
      • Scholarship Application
    • Podcast
    • Documents
    • Chapter YouTube Channel
    • ISPE Publications
    • ISPE Guidance Documents
    • Member Directory
    • ISPE Training
    • ISPE Communities of Practice
  • BLOG
    • Boston Chapter Blog
      • Contribute
    • ISPE Blog
  • CAREERS
    • Job Board
    • Post a Job
  • Gallery
  • SCHOLARSHIP FOUNDATION
    • About the Foundation
    • Apply for a Scholarship
    • Donate
Alnylam’s RNAi Therapeutic Approved by FDA

Alnylam’s RNAi Therapeutic Approved by FDA

  • Posted by ISPE Boston
  • On August 15, 2018

RNAi therapeutics company Alnylam Pharmaceuticals has announced that the FDA has approved Onpattro (patisiran) lipid complex injection, a RNA interference (RNAi) therapeutic for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. Onpattro is the first and only FDA-approved treatment for this indication.

“Alnylam was founded on the vision of harnessing the potential of RNAi therapeutics to treat human disease, and this approval heralds the arrival of an entirely new class of medicines. We believe today draws us ever-closer to achieving our Alnylam 2020 goals of becoming a fully integrated, multi-product biopharmaceutical company with a sustainable pipeline,” said John Maraganore, Ph.D., Chief Executive Officer of Alnylam.

hATTR amyloidosis is a rare, inherited, rapidly progressive and life-threatening disease with a constellation of manifestations. In addition to polyneuropathy, hATTR amyloidosis can lead to other significant disabilities including decreased ambulation with the loss of the ability to walk unaided, a reduced quality of life, and a decline in cardiac functioning.

The FDA approval was based on positive results from the randomized, double-blind, placebo-controlled, global Phase 3 APOLLO study, the largest-ever study in hATTR amyloidosis patients with polyneuropathy. Results from the APOLLO study were published in the July 5, 2018, issue of The New England Journal of Medicine.

Onpattro was reviewed by the FDA under Priority Review and had previously been granted Breakthrough Therapy and Orphan Drug Designations. On July 27, patisiran received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy under accelerated assessment by the European Medicines Agency. Expected in September, the European Commission will review the CHMP recommendation to make a final decision on marketing authorization, applicable to all 28 EU member states, plus Iceland, Liechtenstein and Norway. Regulatory filings in other markets, including Japan, are planned beginning in mid-2018. (Source: Alnylam Website, 10 August, 2018)

Share this
 

0 Comments

Leave Reply Cancel reply

Leave a Comment

Your email address will not be published. Required fields are marked *

Post Categories
  • Podcasts (1)
  • Industry Buzz (557)
  • Chapter News (536)
  • Knowledge & Training (79)
  • Students & YP (78)
  • Career Tools (13)
Get Updates via Email




“What, Me Worry?” Risk Management & Quality at the Product Show

Previous thumb

About RNAi & Alnylam

Next thumb
Scroll
Follow Us
Search this Site
@2024 ISPE Boston Chapter. All rights reserved.